Watch PCRX. Know when insiders buy.
One email the day a filing lands. Free.
PCRX
Pacira BioSciences, Inc.
25.56
+0.93 +3.78%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1BP/E 73.0DIV YIELD —FCF YIELD 17.62%REV TTM $746.2M +5.7%NET INCOME $14.6MNET DEBT $157.2M52W 19.16 – 27.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $192.4M | +6.2% | 77.0% | $4.3M | $4.7M | — | 0.12 | $57.5M | $1.3M | $56.1M | Aug 4 |
| Q1 2026 · Mar 31 | $177.4M | +5.0% | 79.5% | $6.9M | $2.9M | −39.4% | 0.07 | $25.7M | $2.7M | $23M | Apr 30 |
| Q4 2025 · Dec 31derived | $196.9M | +5.1% | 79.5% | $2.3M | $1.6M | −89.8% | 0.04 | $43.7M | $218K | $43.5M | Feb 26 |
| Q3 2025 · Sep 30 | $179.5M | +6.5% | 80.9% | $6.4M | $5.4M | — | 0.12 | $60.8M | $3.9M | $57M | Nov 6 |
| Q2 2025 · Jun 30 | $181.1M | +1.7% | 77.4% | $8.5M | −$4.8M | −125.7% | -0.11 | $12M | $2.7M | $9.3M | Aug 4 |
| Q1 2025 · Mar 31 | $168.9M | +1.1% | 79.7% | $2M | $4.8M | −46.4% | 0.10 | $35.5M | $8.5M | $26.9M | Apr 30 |
| Q4 2024 · Dec 31derived | $187.3M | +3.3% | 78.7% | $24.7M | $16M | −35.5% | 0.35 | $33.1M | $2.1M | $31M | Feb 26 |
| Q3 2024 · Sep 30 | $168.6M | +2.8% | 76.9% | −$139.5M | −$143.5M | −1421.3% | -3.11 | $53.9M | $4.1M | $49.8M | Nov 6 |
| Q2 2024 · Jun 30 | $178M | — | 75.1% | $28.2M | $18.9M | — | 0.39 | $53.2M | $1.6M | $51.6M | Aug 5 |
| Q1 2024 · Mar 31 | $167.1M | — | 71.6% | $13.2M | $9M | — | 0.19 | $49.1M | $2.8M | $46.3M | May 8 |
| Q4 2023 · Dec 31derived | $181.2M | — | 73.7% | $33.2M | $24.9M | — | 0.52 | $47.6M | $1.8M | $45.8M | Feb 26 |
| Q3 2023 · Sep 30 | $163.9M | — | 75.8% | $17.7M | $10.9M | — | 0.23 | $44.4M | $3.4M | $41M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $726.4M | 79.4% | $19.2M | $7M | 1.0% | 0.16 | $152M | $15.3M | $136.7M | $148.3M | — |
| FY2024 · to Dec 31 | $701M | 75.7% | −$73.4M | −$99.6M | -14.2% | -2.15 | $189.4M | $10.6M | $178.8M | $25M | — |
| FY2023 · to Dec 31 | $675M | 72.6% | $87.7M | $42M | 6.2% | 0.89 | $154.6M | $15.2M | $139.5M | $0 | — |
| FY2022 · to Dec 31 | $666.8M | 70.1% | $60M | $15.9M | 2.4% | 0.34 | $145.3M | $30.1M | $115.2M | $0 | — |
| FY2021 · to Dec 31 | $541.5M | 74.1% | $89.9M | $42M | 7.8% | 0.92 | $125.7M | $45.9M | $79.9M | — | — |
| FY2020 · to Dec 31 | $429.6M | 72.7% | $46.4M | $145.5M | 33.9% | 3.33 | $77M | $37.8M | $39.2M | — | — |
Every number comes from Pacira BioSciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.